IMMUNO-ONCOLOGY

 

WHERE TO FIND US

• The Christie NHS Foundation Trust
• MCRC building
• The University of Manchester
• CRUK MI

Our researchers are interested in how tumours evade the immune system, and how the immune system can be harnessed to target cancer cells. Their work is coordinated through the cancer branch of the newly-created Lydia Becker Institute of Immunology and Inflammation and the Manchester IO Network. This network brings together scientists and clinicians working in the field of Immuno-Oncology to enhance collaboration and education with the aim of developing future studies across Manchester.

Scientists from the Cancer Research UK Manchester Institute are looking at the mechanisms underlying natural and therapy-induced tumour immunity, and the dual role of inflammation in cancer, with an overall goal to develop novel targeted interventions to disrupt immune suppression and enhance the efficacy of therapy.

In the University’s Division of Cancer Sciences, several groups are exploring various immunotherapy approaches. One team is investigating the combination of immunotherapy and radiotherapy: researchers are assessing how radiation can enhance anti-tumour immunity and how immunotherapy can be used to overcome radioresistance. Others are focused on the pre-clinical study of cell therapies, including CAR T-cell therapy and tumour infiltrating lymphocyte (TIL) therapy.

Within Pharmacy, our scientists are validating novel immunomodulatory approaches to the treatment of breast cancer and therapeutics that target cancer-associated inflammation, as well as understanding inflammatory responses during tumour growth, progression and therapy response.

At The Christie NHS Foundation Trust, clinicians are conducting a range of trials of novel immunotherapies, including agents that target arginase, PD-L1 and PD1. Linking into this, our Tumour Immunology and Inflammation Monitoring Laboratory (TIIML) is developing and implementing immune-based biomarker assays for use in such clinical studies.

The iMATCH consortium, which consists of The Christie, The University of Manchester, Manchester University NHS Foundation Trust (including Royal Manchester Children’s Hospital and Manchester Royal Infirmary) and nine life science focused businesses, is funded by Innovate UK and will enable us to scale up and run larger clinical trials of advanced therapies.

PEOPLE

Biology

Clinical Oncology

Gynaecology

Informatics

Medical Oncology

Pathology

  • Anshuman Chaturvedi